DSpace Repository

Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial.

Show simple item record

dc.contributor.author Mahdavinasab, SM
dc.contributor.author Saghazadeh, A
dc.contributor.author Motamed-Gorji, N
dc.date.accessioned 2019-06-26T06:01:47Z
dc.date.available 2019-06-26T06:01:47Z
dc.date.issued 2019-04-12
dc.identifier.other DOI: 10.1007/s00787-019-01333-5
dc.identifier.uri https://link.springer.com/article/10.1007%2Fs00787-019-01333-5
dc.identifier.uri http://dspace.uswr.ac.ir/xmlui/handle/123456789/290
dc.description.abstract Increasing evidence suggests that the function of the GABAergic system is abnormally low in autism spectrum disorder (ASD). Baclofen, which functions as a selective agonist for GABAB receptors, does appear promising for the treatment of ASD. We conducted a 10-week randomized-controlled study aimed at evaluating the potential of baclofen as an adjuvant therapy to enhance the effect of risperidone in children with ASD. Sixty-four children (3-12 years) with moderate-to-severe irritability symptoms of ASD were included. We used the Aberrant Behavior Checklist-Community Edition (ABC-C) for the outcome measures on each of the follow-up visits (weeks 0, 5, and 10). Analysis of the combined data revealed significant improvement for all the ABC subscales (irritability: F = 51.644, df = 1.66, p < 0.001, lethargy: F = 39.734, df = 1.38, p < 0.001, stereotypic behavior: F = 25.495, df = 1.56, p < 0.001, hyperactivity: F = 54.135, df = 1.35, p < 0.001, and inappropriate speech: F = 19.277, df = 1.47, p = 0.004). Combined treatment with baclofen and risperidone exerted a greater effect on improvement of hyperactivity symptoms at both midpoint [Cohen's d, 95% confidence interval (CI) = - 3.14, - 5.56 to - 0.72] and endpoint (d, 95% CI = - 4.45, - 8.74 to - 0.16) when compared with treatment with placebo plus risperidone. The two treatments achieved comparable results for other outcome measures. Our data support safety and efficacy of baclofen as an adjuvant to risperidone for improvement of hyperactivity symptoms in children with ASD. en_US
dc.language.iso en en_US
dc.publisher springer Link en_US
dc.subject Autism en_US
dc.subject Baclofen en_US
dc.subject GABA en_US
dc.subject GABAergic inhibition en_US
dc.subject Hyperactivity en_US
dc.subject Randomized-controlled trial en_US
dc.title Baclofen as an adjuvant therapy for autism: a randomized, double-blind, placebo-controlled trial. en_US
dc.type Article en_US
dc.publisher.index scopus pubmed
dc.publisher.index pubmed

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account